Leishmaniasis drug candidate tested in humans for first time – study halted early
NCT ID NCT04504435
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a first-in-human study to check the safety and how the body processes a single dose of GSK3494245, a potential treatment for leishmaniasis. It involved 59 healthy adults who received up to three increasing doses of the drug or a placebo. The study was terminated early, so the full safety and dosing information was not collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK3494245
What could go wrong
This was a very early, first-in-human study that was terminated, so we don't know if the drug is safe or effective. No conclusions can be drawn about treating leishmaniasis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Cambridge, CB2 2GG, United Kingdom